Comparative Pharmacology
Head-to-head clinical analysis: QUELICIN versus SUCCINYLCHOLINE CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUELICIN versus SUCCINYLCHOLINE CHLORIDE.
QUELICIN vs SUCCINYLCHOLINE CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor end-plate, causing persistent depolarization and preventing repolarization, resulting in neuromuscular blockade.
Depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor endplate, causing initial depolarization followed by sustained membrane depolarization and desensitization, leading to muscle paralysis.
1 mg/kg IV bolus for rapid sequence intubation; maintenance infusion 0.5-1 mg/min IV for prolonged procedures.
1-1.5 mg/kg IV bolus for intubation; 2.5-4 mg/kg IM if IV access unavailable.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 minutes in normal patients; prolonged to 20-40 minutes in patients with pseudocholinesterase deficiency.
The terminal elimination half-life of succinylcholine is approximately 2–4 minutes in patients with normal pseudocholinesterase activity. Clinically, this short half-life correlates with rapid offset of neuromuscular blockade. In patients with atypical or deficient pseudocholinesterase, half-life may be prolonged to 20–60 minutes or more.
Primarily hydrolyzed by plasma pseudocholinesterase; less than 2% excreted unchanged in urine; minimal biliary/fecal elimination.
Succinylcholine is rapidly hydrolyzed by plasma pseudocholinesterase. Only 2-10% of the administered dose is excreted unchanged in the urine; the remainder is metabolized to succinylmonocholine and further to succinic acid and choline. Biliary/fecal elimination is negligible.
Category C
Category C
Neuromuscular Blocker (Depolarizing)
Neuromuscular Blocker (Depolarizing)